Botulinum toxin A for the treatment of cervical dystonia

Introduction: Dystonia is more common than many other neurological diseases, such as Huntington's disease, Amyotrophic Lateral Sclerosis and Myasthenia gravis. Its prevalence is 3.4–29.5 per 100 000 for generalized and focal dystonia. Cervical dystonia (CD) is the most current form of adult-onset focal dystonia. The aetiology of CD is unknown, but genetic and environmental factors are implicated. Dystonia can cause significant disability, and the usual therapeutic approach is mainly symptomatic. Botulinum toxin (BTX) is nowadays regarded as first-line treatment for CD and has dramatically improved the quality of…